NCT05551598View on ClinicalTrials.gov

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Mitoxantrone Hydrochloride Liposome Injection

IV, once every 12 weeks (Q12W)

Trial Locations (1)

100000

Xuanwu Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY